Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 249

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Prognostic Value of Baseline Plasma Amino-Terminal Pro-Brain Natriuretic Peptide and Its Interactions With Irbesartan Treatment Effects in Patients With Heart Failure and Preserved Ejection Fraction: Findings From the I-PRESERVE Trial

Anand, Inder S., Rector, Thomas S., Cleland, John G., Kuskowski, Michael, McKelvie, Robert S., Persson, Hans, McMurray, John J., Zile, Michael R., Komajda, Michel, Massie, Barry M., Carson, Peter E.·2011·Circulation: Heart Failure

Abstract

Background—: Plasma concentrations of natriuretic peptides (NPs) are associated with morbidity and mortality in patients with systolic heart failure (HF). However, the role of NP as a prognostic marker in patients with HF and preserved ejection fraction (HFpEF) has not been studied in a large cohort of well-characterized patients. Moreover, it is unclear whether treatments have a differential effect on morbidity and mortality across the spectrum of NP levels. Methods and Results—: N-terminal pro-brain natriuretic peptide (NT-proBNP) was measured at baseline in 3480 patients in the I-PRESERVE (Irbesartan in Heart Failure with Preserved Ejection Fraction Trial). In a multivariable Cox regression model, NT-proBNP above the median of 339 pg/mL was independently associated with an increased risk of the primary end point of all-cause mortality and prespecified cardiovascular hospitalizations (adjusted hazard ratio [HR], 1.79; 95% CI, 1.56 to 2.10; P <0.001); all-cause mortality (adjusted HR, 2.04; 95% CI, 1.68 to 2.47; P <0.001); and a composite of HF events, including death due to worsening HF or sudden death or hospitalization due to worsening HF (adjusted HR, 1.77; 95% CI, 1.43 to 2.20; P <0.001). There were significant interactions between the effect of irbesartan and median split of baseline NT-proBNP for the primary outcome ( P =0.005), all-cause mortality ( P =0.05), and the HF composite outcome ( P <0.001). Use of irbesartan was associated with improved outcomes in patients with NT-proBNP below, but not above, the median. After adjusting for 20 baseline covariates, irbesartan still had a beneficial effect on the primary outcome (HR, 0.74; 95% CI, 0.60 to 90; P =0.003), all-cause mortality (HR, 0.75; 95% CI, 0.56 to 0.99; P =0.046), and HF composite outcome (HR, 0.57; 95% CI, 0.41 to 0.80; P =0.001) in patients with NT-proBNP below the median. Conclusions—: The unexpected benefit of irbesartan in lower-risk patients with HFpEF in this post hoc analysis may indicate effects on early, but not later, high-risk stages of the disease. These findings question the strategy of using elevated plasma concentrations of NP as a patient selection criterion in HFpEF trials. More studies are needed to support or contest this practice. Clinical Trial Registration—: URL: http://www.clinicaltrials.gov . Unique identifier: NCT00095238.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circheartfailure.111.962654

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 249

Metadata

Authors
Anand, I. S., Rector, T. S., Cleland, J. G., Kuskowski, M., McKelvie, R. S., Persson, H., McMurray, J. J., Zile, M. R., Komajda, M., Massie, B. M., & Carson, P. E.
Venue
Circulation: Heart Failure
Published
2011-09
Volume
4
Issue
5
Pages
569-577
ISSN
  • 1941-3289 (ISSN-L)
  • 1941-3297
OpenAlex
W2100166328
Cited by
249
References
2
FWCI
9.43
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prognostic Value of Baseline Plasma Amino-Terminal Pro-Brain Natriuretic Peptide and Its Interactions With Irbesartan Treatment Effects in Patients With Heart Failure and Preserved Ejection Fraction: Findings From the I-PRESERVE Trial. https://app.cochat.ai/papers/10.1161/circheartfailure.111.962654
The paper
Anand, I. S., Rector, T. S., Cleland, J. G., Kuskowski, M., McKelvie, R. S., Persson, H., McMurray, J. J., Zile, M. R., Komajda, M., Massie, B. M., & Carson, P. E. (2011). Prognostic Value of Baseline Plasma Amino-Terminal Pro-Brain Natriuretic Peptide and Its Interactions With Irbesartan Treatment Effects in Patients With Heart Failure and Preserved Ejection Fraction: Findings From the I-PRESERVE Trial. Circulation: Heart Failure. https://doi.org/10.1161/circheartfailure.111.962654

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.